FindTrial
Sign In

Modified molecular subtypes correlate with long-term survival, distinct adjuvant chemotherapy response and immune landscape in small cell lung cancer

Modified molecular subtypes correlate with long-term survival, distinct adjuvant chemotherapy response and immune landscape in small cell lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200061584
Enrollment
Unknown
Registered
2022-06-29
Start date
2022-06-15
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Group 1:No intervention

Sponsors

Fudan University Shanghai Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Pathologically diagnosed as small cell lung cancer; 2. Underwent complete surgical resection at the Department of Thoracic Surgery, Fudan University Shanghai Cancer Center; 3. Pathological tumor slides were available for analysis.

Exclusion criteria

Exclusion criteria: 1. Incomplete clinical and pathological patient data; 2. Extensive-stage small cell lung cancer.

Design outcomes

Secondary

MeasureTime frame
Recurrence-free survival;—

Primary

MeasureTime frame
Overall survival;—

Countries

China

Contacts

Public ContactChaoqiang Deng

Fudan University Shanghai Cancer Center

fdudengcq@163.com+86 19121746070

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026